Effect of Sacubitril/Valsartan on the recurrence of atrial fibrillation after catheter ablatio

Phase 4

Recruiting

• Conditions: Atrial fibrillation; persistent atrial fibrillation, catheter ablation; C14.280.067.198

• Registration Number: JPRN-jRCT1061230045
• Lead Sponsor: akano Yukiko

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Patients who are aged 20 years and older, and younger than 80 years.
2. Patients who are scheduled to undergo catheter ablation for persistent atrial fibrillation at the first time, and with hypertension.
3. Patients who give written informed consents before treatment.

Exclusion Criteria

1. NYHA class4
2. Hyperthyroidism or hypothyroidism
3. Moderate or severe mitral disease
4. Severe renal dysfunction(eGFR<30ml/min/1.73m2)
5. The presence of a prosthetic heart valve
6. Presence of thrombus in left atrial appendage on transesophageal echocardiography
7. History of hypersensitivity to Sacubitril/Valsartan or Valsartan
8. History of angioedema due to angiotensin 2 receptor antagonist or angiotensin convertinf enzyme inhibitor , Hereditary/Aquired Angioedema, or idiopathic angioedema
9. Administration of aliskiren fumarate to diabetes mellitus
10. Severe hepatic dysfunction(Child Pugh C)
11. Pregnant, unwilling to practice contraception during the study, or lactation female
12. Patients who are participating, or intend to participate in other clinical trials during the study
13. Patients who obstruct, bind or confuse the specific assessment about protcol in the study
14. Principal Investigator involving in the study, or employees of the participating medical center, or their family

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reccurence rate of atrial fibrillation 12 months after catheter ablation

Secondary Outcome Measures

Name	Time	Method
Supraventricular arrhythmias lasting >24 hours<br>Left atrial diameter and left atrial volume, peak atrial longitudinal strain